About GLP Stack Guide
Independent, research-backed education for the tens of millions of people on GLP-1 weight-loss medications who want to understand — and prevent — lean muscle loss.
Why this site exists
GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound are among the most effective weight-loss medications ever developed. They work. But clinical trial data is clear that roughly 25–45% of the weight lost on these drugs comes from lean muscle mass, not fat — a number most prescribing doctors don't mention and most patients don't discover until they notice something has changed.
This site exists because the information gap is wide. Tens of millions of people are on these medications in the U.S. alone. The research on how to preserve muscle during GLP-1 therapy is real and actionable. The quality educational content that explains it clearly, with real citations, without selling anything? Nearly nonexistent.
GLP Stack Guide fills that gap.
What we cover
- The science of GLP-1 drug effects on body composition — what the trials actually show
- Evidence-based strategies for preserving lean mass during active weight loss
- Comparisons between drugs (semaglutide vs. tirzepatide) across different outcome measures
- Research on emerging compounds in the metabolic health space — explained accurately, with real citations and honest uncertainty
- Body composition tracking: what to measure, how to measure it, and why the scale alone misleads you
- Regulatory updates relevant to the research peptide and metabolic health space
Our editorial standards
We cite primary sources
Every factual claim in our articles links to a primary source — the actual published study, clinical trial, FDA document, or consensus guideline. No paraphrasing from other blogs. No citations to "experts say."
We disclose what we don't know
Emerging research is often preliminary. When a finding comes from animal models only, or from a preprint that hasn't been peer-reviewed, or when two studies directly contradict each other — we say so explicitly. We do not present uncertain findings as established facts.
We don't sell false hope
Some of what gets discussed in the GLP-1/metabolic health space is genuinely promising research. Some of it is extrapolated beyond what the evidence supports. We distinguish between the two. If a combination of compounds has never been studied in human clinical trials, we say that — even if the mechanistic rationale is compelling.
We are not your doctor
Nothing on this site constitutes medical advice. Every article carries a disclosure. We exist to help you understand the research landscape so you can have better-informed conversations with your healthcare provider — not to replace that conversation.
Affiliate disclosure
Some links on this site are affiliate links (TruDiagnostic is the primary example). If you purchase through those links, we may earn a commission. This does not affect what we recommend or how we frame it — we only link to tools we believe are scientifically credible. Affiliate relationships are disclosed in every article where they appear.
Who writes here
Articles are written by the GLP Stack Guide editorial team and medically reviewed by a board-certified physician before publication. Reviewer credentials are listed on each article.
We don't have a financial relationship with any pharmaceutical company, GLP-1 drug manufacturer, or compounding pharmacy. Our revenue comes from affiliate commissions on research tools we believe in (like epigenetic testing), not from drug or supplement advertising.
Get in touch
Questions, corrections, or suggestions? Reach us at: hello@glpstackguide.com
If you find a factual error in any article, please tell us. We'll verify and correct it, and note the correction at the bottom of the article.